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Summary: A simple method is described for the simultaneous determination of alkaline phosphatase (EC 3.1.3.1)
and 5'-nucleotidase (EC 3.1.3.5) iri serum. The method is based on the determination of inorganic phosphorus
released by the action of the two enzymes on adenosine-S'-monophosphate at pH 9.5 (200 mmol/1 tris-buffer) in
the presence and absence of ,-cysteine. This amino acid at a concentration of 2-10 mmol/1 was found to be a
specific inhibitor for alkaline phosphatase but with no effect on 5'-nucleotidase activity.
Simultanbestimmung der Aktivitäten von 5 '-Nucleotidase und alkalischer Phosphatase im Serum
Zusammenfassung: Eine einfache Methode zur gleichzeitigen Bestimmung von alkalischer Phosphatase (EC 3.1.3.1)
und 5'-Nucleotidase (EC 3.1.3.5) im Serum wird beschrieben. Die Methode beruht auf der Bestimmung des durch
beide Enzyme aus 5'-AMP bei pH 9,5 (200 mmol/1 Trispuffer) freigesetzten Phosphats in Gegenwart und Abwesen-
heit von ,-Cystein. 2-10 mmol/1 Cystein erwiesen sich als spezifischer Hemmstoff für alkalische Phosphatase ohne
Effekt auf die Aktivität von 5'-Nucleotidase.
Introduction
Phosphatase was the first enzyme of diagnostic im-
portance to be recognized (1). Alkaline phosphatase
and 5'-nucleotidase determination in serum have proved
to be satisfactory diagnostic enzymes. Serum alkaline
phosphatase is raised in a variety of conditions particular-
ly in hepatobiliary or osteöblastic disorders (2—5). Serum
activity can be determined by measuring the rate of
hydrolysis of a suitable primary phosphate ester at an
alkaline pH (6-14).
5'-Nucleotidase is an alkaline phosphomonoesterase
which was first discovered by Reis (15), who showed
that it is activated by magnesium and inhibited by nickel
ions. Its activity is confined to the hydrolysis of nucleo-
tide pentose-S'-monophosphate group. Elevated levels of
serum 5'-nucleotidase activity are almost exclusively
confined to hepatobiliary disease, especially obstructive
jaundice (2-5). In contrast to serum alkaline phosphatase,
normal activities of 5'-nucleotidase occur to Page f* and
other bone diseases (4). These observations have been
confirmed by Young (3). The main difficulty in deter-
ming 5'-nucleotidase activity is the interference of
alkaline phosphatase. Trials have been carried out by
many investigators to eliminate this interference, but
without satisfactory results (2,3,4).
The aim of the present study is to establish a method for
measuring simultaneously the activities of 5'-nucleotidase
and alkaline phosphatase in serum. The method is based
on the determination of the inorganic phosphorus rele-
ased by the action of the two enzymes on adenosine-S'-
monophosphate at pH 9.5 in tris-buffer (200 mmol/1) in
the presence and absence of ,-cysteine. This amino acid
was found to be a specific inhibitor for serum alkaline
phosphatase but with no effect on 5'-nuclebtidase acti-
vity.
Materials and Methods
Reagents required
for the established method mentioned in table 1, are:
1. Buffer/activator (0.4 mol/1 tris-HCl buffer pH 9.5/0.02 mol/1
Mg»)
Dissolve 24.2 g. Tris(hydroxymethyl)methylamine, and 2.0 g
of MgCi2 · 6H2O (A.R grade) in about 480 ml distilled water.
Adjust the pH to 9.5 with HC1 and dilute to 500 ml with
water. The solution is stable at 4 °C.
2. Alkaline phosphatase inhibitor (0.1 mol/1 ,-cysteine)
Dissolve 0.31 g of -cysteine hydrochloride in about 15 ml
distilled water. Adjust the pH to 9.5 with 100 g/1 NaOH, dilute
to 20 ml with water. The solution is stable for only four days,
in closed container at 4 °C. ·
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Tab. 1.
Procedure:
To a series of test tubes the amounts of the following reagents are added
Tris-buffer/Mg++
Distilled water
Λ-cysteine
Serum
ml
0.5
0.1
0.2
B
ml
0.5
—
0.1
0.2
Test blank
ml
0.5
0.1
0.2
standard
ml
-
-
Reagent
blank
ml
-
-
Substrate
Cold trichloroacetic acid
Substrate
Standard
Trichloroacetic acid
Ammonium molybdate
Ascorbic acid
Mix, incubate at 37 °C for 5 min then add,
0.2 0.2
Incubate at 37 °C for 60 min, stop the reaction by adding
3.0 3.0 3.0
0.2
Mix, stand for 5 min, centrifuge take aliquote of,
2.0 2.0 2.0
1.0 1-0 1.0
0.5 0.5 0.5
0.5 0.5 0.5
Mix, stand for 20 min, read at 640-720 nm against the test blank for the test and against reagent
blank for the standard
0.5
2.5
0.5
0.5
3.0
0.5
0.5
A = Total phosphatase activities
B = 5'-Nucleotidase activity
Α-B = Alkaline phosphatase activity
Calculation:
E 640 test
E 640 standard
X 0.64 (μπιοί PJ) X 1000 (per litre)60 (time) X 0.1 (ml of serum used) [U/IJ
3. Buffered substrate (0.025 mol/1 adenosine-5'-monophosphate)
Dissolve 0.4 g of adensoine-5'-monophosphate di-sodium salt
in 40 ml of 0.05 mol/1 tris-HCl pH 9.5. This solution is stable
at - 20 °C
4. Trichloroacetic acid
Dissolve 100 g in one litre of distilled water and keep at 4 °C.
•5. Ammonium molybdate.
Dissolve 10 g in one litre of distilled water. The solution is
stable at room temperature.
6. Reducing agent solution
Use freshly prepared ascorbic acid at a concentration of 2 g/1.
7. Standard phosphorus solution.
Dissolve 43.92 mg of potassium dihydrogen phosphate in
250 ml distilled water and add a few drops of chloroform.
Use 0.5 ml of this solution which contains 0.64 μπιοί phos-
phorus. Keep at 4 °C.
Enzyme assay
5'-Nucleotidase and alkaline phosphatase activities were assayed
according to the method outlined in Table 1. Through the course
of this studies, unless stated otherwise, F" was 10 mmpl/1; CN"
was 5 mmol/1 and L-cysteine was 10 mmol/1. Adenosine-5'-mono-
phosphate (5 mmol/1) and 0-glycerophosphate (5 mmol/1) were
used in parallel in this investigation. Tris-buffer (200 mmol/1) was
used to cover the range pH 7.5 to 9.5 while glycine buffer
(50 mmol/1) was used for the range pH 9.5 to 10.5. The pH was
checked after the addition of all reagents and no change was ob-
served. The activity assayed in the presence of 5'-AMP as sub-
strate corresponds to both 5;-nucleotidase and alkaline phos-
phatase while that assayed in the presence of 0-glycerophosphate
corresponds to alkaline phosphatase.
Results
The pH activity curves of human liver homogenate
with 5'-AMP and j3-glycerophosphate as substrate are
shown in figure 1 and 2 respectively. While those for
kidney homogenate are shown in figure 3 and 4. As
shown in figure 1, 5'-nucleotidase was completely inhi-
bited by F~ while alkaline phosphatase of liver was in-
hibited by 35 % at pH 9.5 (fig. 2). Also it was found that
5'^nucleotidase of both liver and kidney were not affec-
ted by CN" or Ζ,-cysteine while alkaline phosphatase was
almost completely inhibited by these agents. As shown
in figure 1 and 3, 5'^nucleotidase showed a broad pH?
activity curve (pH 7.5—9.5) while alkaline phosphatase
showed a narrower range (pH 9.5 to 10.5) as illustrated
in figure 2 and 4. It is worth noting that the activity of
alkaline phosphatase in glycine buffer at pH 9.5 is lower
than that in tris-buffer at the same pH; an exception was
found with liver and 5'-AMP where the higher values were
obtained with glycine buffer (fig. 1).
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Fig. 1. pH-Activity curve of human liver homogenate, 5'-AMP
(5 mmol/1) as substrate. ( ) Tris buffer 200 mmol/1 and
( ) glycine buffer 50 mmol/1. (·) None, (o) 10 mmol/1 F",
(A) 5 mmol/1 CN" and (Δ) 10 mmol/11-cysteine.
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Fig. 3. pH-Activity curve of human kidney homogenate, 5'-AMP
(5 mmol/1) as substrate. ( ) Tris-buffer 200 mmol/1 and ( )
glycine-buffer 50 mmol/1. (·) None, (o) 10 mmol/1 F", (A)
5 mmol/1 CN", and (Δ) 10 mmol/1 /,-cysteine.
Fig. 2. pH-Activity curve of human liver homogenate, 0-glycero-
phosphate (5 mmol/1) as substrate. (——) Tris buffer 200 mmol/1)
( ) glycine buffer 50 mmol/1. (·) None, (o) 10 mmol/1 F",
(4) 5 mmol/1 CN", and (Δ) 10 mmol/1 L-cysteine.
Fig. 4. pH-Activity curve of human kidney homogenate, 0-gly-
cerophosphata (5 mmol/1) as substrate. ( ) Tris-buffer 200
mmol/1 and ( ) glycine-buffer 50 mmol/1. (β) None, (o)
10 mmol/1 F", (*) mmol/1 CN", and (Δ) 10 mmol/1 £-cysteine.
A comparative study was carried out to determine
whether alkaline phosphatase isoenzymes of animal
tissues are different in their behaviour from those of
human, and whether the different alkaline phosphatase
isoenzymes of human tissue homogenates or purified
human alkaline phosphatase preparation showed different
sensitivities towards F", CN" and cysteine. The result is
represented in table 2. Activities of 5'-nucleotidase and
alkaline phosphatase were measured at pH 9.5 which was
found to be in the optimal range for both enzymes.
Generally, F" inhibit 5'-nucleotidase with no or little
effect on alkaline phosphatase while Ζ,-cysteine or CN"
inhibit alkaline phosphatase but not 5'-nucleotidase.
However, only in mouse liver homogenate was alkaline
phosphatase inhibited by 60 % in the presence of F" and
not affected by CN~ or I-cysteine. Alkaline phosphatase
of washed heavy particles (which contain nuclei and
plasma membrane, the latter being the site of alkaline
phosphatase and 5'-nucleotidase) prepared from mouse
liver homogenate was not affected by F" and it was com-
pletely inhibited either by CN" or Z,-cysteine.
In the homogenate, £-cysteine or CN" inhibit the alkaline
phosphatase of human liver by 75 %, and the alkaline
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Tab. 2. The effect of fluoride, cyanide and Ζ,-cysteine on S'-nucleotidase and alkaline phosphatase activities in animal and human
tissues, at pH 9.5 (tris-buffer)
Agent Type of tissue
Liver . Kidney Intestine
5'-AMP -GP p-NPP 5'-AMP -GP p-NPP 5'-AMP -GP p-NPP
Mouse
None
Human
Mouse
10 mmol/l
F~ Human
Mouse
5 mmol/l
CN" Human
Mouse
10 mmol/l
L- Human
Cysteine
Homogenate8
Heavy particles'5
Homogenate3
Purified0
Homogenate3
Heavy particlesb
Homogenate3
Purified0
Homogenate3
Heavy particlesb
Homogenate3
Purified0
Homogenate3
Heavy particles'5
Homogenate3
Purified0
3.0
0.7
2.45
3.2
32
11
50
100
108
91
80
10
153
130
82
0
0.71
0.15
1.25
4.0
38
85
84
100
95
10
25
10
95
10
26
0
0.68
1.26
3.8
37
92
100
95
-
27
14
90
—
23
0
17.0
3.05
1.12
59
33
100
58
—
84
8
50
—
84
3
19.0
1.50
1.37
93
80
100
14
—
10
7
8
—
10
4
20.0 ,
2.30
1.07
100
70
100
31
—
43
0
31
—
39
0
28.0
23.0
3.80
93
98
100
15
—
16
3
15
—
16
0
34.0
r25.5
5.8
95
100
100
3
—
11
3
1
~~~
7
0
21.0
22.5
4.0
100
98
100
18
~~
48
6
23
~"
48
3
Results tabulated as:
Activity values expressed as μιηοΐ P[/min · g wet tissue and as μηιοί Pj/min · mg protein purified enzyme resp. as per cent,
taking activity with Mg4* alone as 100 per cent
a) Tissues were homogenized in distilled water and aliquots equivalent to 10 mg of liver and 2 mg of kidney or intestine were used
for the enzyme assay with an appropriate period of incubation.
b) Heavy particles was prepared by centrifuging mouse liver homogenate at 1000 g for 10 min; then the pellet was washed three
times with distilled water.
c) Purified preparation of alkaline phosphatase from human liver, kidney and intestine according to Schlamowitiz (16).
0-GP = 0-glycero phosphate; p-NPP = p-nitrophenylphosphate
phosphatase of kidney and intestine by 90 %. A prepa-
ration of purified human alkaline phosphatase isoen-
zymes was completely inhibited when 5'-AMP, /3-glycero-
phosphate or p-nitrophenylphosphate were used as sub-
strates. These results indicate that mouse liver alkaline
phosphatase in tissue homogenates differs from that of
human with respect to the effect of F", CN" and Ζ,-
cysteine, whereas in human tissue homogenate the
liver alkaline phosphatase isoenzyme was less inhibited
by Ζ,-cysteine than the kidney or intestine isoenzymes.
The effect of different concentrations of Ni*+, F", CN"
and Ζ,-cysteine on the activities of serum 5'-nucleotidase
and alkaline phosphatase are shown in figure 5 and 6.
When 5'-AMP was used as substrate (fig. 5), F" (5-10
mmol/l) inhibited S'-nucleotidase but not alkaline phos-
phatase. In the presence of Ζ,-cysteine (2-10 mmol/l)
or CN" (2-5 mmol/l) alkaline phosphatase, but not 5'-
nucleotidase was completely inhibited. Nickel ions at a
t concentration of 1-10 mmol/l were found to inhibit
both enzyms, (under these condition Ni++ was not
precipitated).
Using 200 mmol/l tris-buffer and 5'-AMP as substrate,
in the presence of Ζ,-cysteine or CN", a broad range for
the maximal activity of serum S'-nucleotidase was
obtained between pH 7.5—9.5 and it was completely
inhibited by F" as shown in figure 7. On the other hand
alkaline phosphatase showed a narrower range (pH 9.5—
10.5) in the presence of F" and was completely inhibited
by CN" and Ζ,-cysteine as illustrated in figure 8.
The time course of S'-nucleotidase and alkaline phospha-
tase activities in normal serum, using S'-AMP, was linear
over three hours incubation as demonstrated in figure 9.
The rates of hydrolysis of 5'-AMP, 0-glycerophosphate
and p-nitrophenylphosphate by serum phosphatases and
by purified alkaline phosphatase of human liver, kidney
and intestine, in the presence and absence of F" or Ζ,-
cysteine are shown in table 3.
Serum S'-nucleotidase was found to be activated by Mg4"1"
more than alkaline phosphatase. The optimal Mg"1"1" con-
centration for maximal S'-nucleotidase and alkaline phos-
phatase activities was found to be in the range of 5—10
mmol/l. 5'-AMP, at a concentration of 20 mmol/l slightly
inhibited alkaline phosphatase, while a concentration of
5-10 mmol/l was found to be sufficient for the assay of
both S'-nucleotidase and alkaline phosphatase.
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Fig. 5. Effect of different inhibitor concentrations on the activi-
ties of serum S'-nucleotidase and alkaline phosphatase at pH 9.5
tris-buffer (200 mmol/l). 5'-AMP (5 mmol/l as substrate, (o) F",
(·) NF, (A) CN", and (Δ) I-cysteine.
2 4 6 8 1 0
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Fig. 6. Effect of different inhibitor concentrations on the activity
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Fig. 7. pH-Activity curve of human serum of patient with liver
metastases, 5'-AMP (5 mmol/l) as substrate. ( ) Tris buffer
200 mmol/l and ( ) glycine buffer 50 mmol/l. (·) None,
(o) 10 mmol/l F", (A) 5 mmol/l CN" and (Δ) 10 mmol/l I-cysteine.
Fig. 8. pH-Activity curve of human serum of patient with liver
metastases., 0-glycerophosphate (5 mmol/l) as substrate. ( )
ofserum alkaline phosphatase at pH 9.5 tris-buffer (200 mmol/l), Tris-buffer, 2oVmmoi/l, (-—) glycine-buffer 50 mmol/l. (·)
-- .. ·*^ . . . f -^ **- X _ V VTM+ / . \ *. x v - A , ,. »,- x v - . 1. Λ»»_ . χ ν - A . f.
^lycerophpsphate (5 mmol/l) as*substrate, (o) F~, (·) NP*f
CN" and (Δ) /,-cysteine.
None, (o) 10 mmol/l F"| (A) 5 mmol/l CN~ and (Δ) 10 mmol/l
Z-cysteine.
Tab. 3. Rate of hydrolysis of 5'^ AMP, /?-giycerophosphate (/J-GP) and p-nitrophenylphosphate (p-NPP) with human serum (liver meta-
stases) and purified alkaline phosphatase of human liver, kidney, and intestine.
Substrate Serum
5 mmol/l
5'-AMP
0-GP
p-NPP
None
(232)
100
70
56
Liver
F~ L-cysteine None
(132)
100
140
107
(104)
100
2
2
(3.2)
100
127
82
Kidney Intestine
F" L-cysteine None F"
(3.2) (0.0)
100
130
80
(1.0)
100
155
100
(1.1)
100
150
88
jL-cysteine None
(0.0) (3.8)
100
150
100
F-
(3.8)
100
140
100
£-cysteine
(0.0)
—
-
—
Activity with 5'-AMP substrate was taken as 100 %
() Activity expressed as μΐηοΐ Pj/min · mg protein for purified enzyms, and as U/l for serum,
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Discussion
Determination of S'-nucleotidase activity in serum is
based on either measuring the amount of inorganic
phosphorus released by the action of the enzyme accor-
ding toFiske &Subbarow (17,18), the decrease in the
optical density of adenosine, released by deamination
of the adenosine-5'-monophosphate in tfce presence of
adenosine deaminase (19), or by measuring the amount
of ammonia, (which is proportional to the S'-nucleo-
tidase activity) released after deamination of adenosine,
by the indophenol reaction (20,21) first reported by
Berthelot (22).
The phosphorus method used for 5'-nucleotidase deter-
mination in serum is essentially based on measuring the
enzyme activity in the presence and absence of 1 mmol/1
Ni**. The difference in activities is assumed to represent
the specific 5'-nucleotidase activity. Criticism had been
made against using Ni** (21) since it was found to in-
hibit human bone and liver alkaline phosphatase (23, 24).
Young (3) corrected for non-specific phosphatase by
preincubating serum with 1.5 mmol/1 EDTA which
should inactivate more alkaline phosphatase than 5'-
nucleotidase. Kowlessar and coworkers (2) estimate 5'-
nucleotidase in the presence of high concentration of
Mg"1"1" which would inhibit alkaline phosphatase comple-
tely. Any proof for these conditions of inactivation is
lacking in their reports. Dixon & Purdon (4) estimated
the alkaline phosphatase contribution to the hydrolysis
of 5'-AMP by measuring the hydrolysis of phenyl phos-
phate at pH 7.5. By subtracting the latter activity from
the activity with 5'-AMP the specific 5'-nucleotidase
activity would be determined. The disadvantages of this
correction lies in the fact that the rate of hydrolysis of
both substrates by the different isoenzymes of alkaline
phosphatase is not equal (25).
All methods mentioned above for determination of
5'-nucleotidase were inadequate in preventing the inter-
ference of alkaline phosphatase. In the present study we
were able to completely and specifically inhibit alkaline
phosphatase in serum by Ζ,-cysteine at a concentration of
2-10 mmol/1, without any effect on 5'-nucleotidase
activity (Table 3, fig. 7 and fig. 8).
Agus et al (26) reported that cysteine and its analogues
inhibit alkaline phosphatase of human kidney and that
from different tissues, cell cultures and£ coll They
found that the inhibition can be reversed by Η2Ο2, Ζη**
or passage through Sephadex G-25. They suggested that
i-cysteine inhibits alkaline phosphatase by chelation of
the zinc atom at the active site of the enzyme. Cox &
Macleod (27) reported also that alkaline phosphatase of
established human cell cultures was repressed by cysteine
or cystine. They claimed that this repression is caused
by the interference with enzyme synthesis or activation
rather than by SH inhibition of alkaline phosphatase.
0 60 120
incubation time [min]
Fig. 9. Time-activity course of human serum 5'-nucleotidase and
alkaline phosphatase in absence (·) and presence of 10 mmol/1 F"
(o) and 10 mmol/I I-cysteine (Δ), 5'-AMP (5 mmol/I) as substrate.
200 mmol/I tris-buffer pH 9.5.
The effect of different concentration of tris-buffer (pH
9.5) on the activities of 5'-nucleotidase and alkaline
phosphatase was tested. The activity of 5'-nucleotidase
in the presence of 25-200 mmol/1 tris was not affected,
while 25-50 mmol/1 was not sufficient for optimal acti-
vity. Accordingly 100-200 mmol/1 was found to be
convenient for the assay of both enzymes.
The level of serum 5'-nucleotidase and alkaline phos-
phatase activities in normal and different pathological
conditions are represented in table 4. Cases with ele-
vated 5'-nucleotidase and alkaline phosphatase (hepa-
toma, and liver metastases) as well as cases with normal
5'-nucleotidase and elevated alkaline phosphatase Qym-
phoma with bone metastases) are included to evaluate
the applicability of the method.
Tab. 4. The level of serum 5'-nucleotidase and alkaline phospha-
tase activities in normal and in different pathological conditions
of Egyptian subjects.
U/l
No. of 5'- Alkaline
cases Nucleotidase Phosphatase
Normal adult
Carcinoma of head
of pancreas
Hepatoma
Breast cancer with
liver metastases
Lymphoma with bone
metastases
Lymphoma with liver
metastases
204
5
10
10
8
10
9.0 ± 4
144.0 ± 63
63.0 ± 46
63.0 ± 33
13.5 ± 4.5
79.0 ± 38
21 ± 6
130 ± 54
49 ±26
54 ±35
55 ±22
87 ±24
Activity measured using 5'-AMP as substrate in presence and
absence of 10 mmol/1 L-cysteine.
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It was reported byFishman et al. (28) that L-cysteine
and analogues inhibit intestinal alkaline phosphatase but
spare that of liver. Our results on tissue homogenates of
mouse agreed with their findings, but we found that
L-cysteine inhibits alkaline phosphatase of human liver
homogenate by only 75 %.
Purified human liver alkaline phosphatase (Table 2),
serum alkaline phosphatase of liver origin (fig. 8) and
alkaline phosphatase of washed heavy particles iso-
lated from mouse liver homogenate were completely
inhibited by L-cysteine (Table 2). These data indicate the
possibility of an endogenous component in liver homo-
genate which stops or abolishes the action of L-cysteine
and CN" on liver alkaline phosphatase.
Therefore, in so far as the different alkaline phosphatase
isoenzyme is present in the soluble form (serum) or free
from other cell components (washed heavy particle from
liver homogenate or purified alkaline phosphatase), L-
cysteine can be used as a specific alkaline phosphatase in-
hibitor, especially if we take into consideration that L~
cysteine (2—10 mmol/1) has no inhibitory effect on
serum 5'-nucleotidase.
It is of interest to notice that £-cysteine activates 5'-
nucleotidase in liver homogenate by 30-50 %, but not
in kidney, intestine or serum (Table 2). Although the
mechanism of activation is not yet clear, it might be
due to the removal of endogenous inhibitor.
Using tris-buffer (200 mmol/1), serum 5'-nucleotidase
showed a broad pH optimum (7.5—9.5) which allows
the enzymatic assay of both alkaline phosphatase and 5'-
nucleotidase to be carried at pH 9.5. Our results with
glycine buffer agreed with those reported by Hausamen
et al (29) who found that glycine had an inhibitory
effect on alkaline phosphatase. The rate of hydrolysis
of 5'-AMP by alkaline phosphatase under these con-
dition at pH 9.5 was equal to that of /?-nitrophenylphos-
phate and less than jS-glycerophosphate by about 40 %.
In normal adult Egyptian subjects (204 cases), using this
method, the 5'-nucleotidase level in serum was found to
be 9.0 ± 4 U/l (ranging from 2-14) which is in good
agreement with the reported values (18, 20). However
the serum alkaline phosphatase level was found to be 21
± 6 U/l. In the serum of different pathological condi-
tions the results were in good agreement with the clini-
cal diagnosis as shown in cases with high 5'-nucleoti-
dase and alkaline phosphatase (hepatoma or liver meta-
stases), or with normal S'-nucleotidase but high alkaline
phosphatase (bone metastases) as shown in Table 4.
This method has many advantages over the methods in
current use. Firstly, one can assay the activity of
5'-nucleotidase and alkaline phosphatase simultaneously
without the interference of one enzyme with the other.
It saves time especially when there are many samples to
be assayed. Secondly, the method is sensitive providing
it is applied as mentioned above. Under these conditions
we were able to estimate phosphorus in concentrations
as low as 0.09 μπιοΐ. Thirdly, few reagents are needed to
run the assay for the two enzymes, which makes it cheap
for routine analysis.
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